ANTI-MÜLLERIAN HORMONE LEVELS AND BREAST CANCER RISK IN THE STUDY OF WOMEN'S HEALTH ACROSS THE NATION

Grimes NP, Bertone-Johnson ER, Whitcomb BW, Sievert LL, Crawford SL, Gold EB, Avis NE, Greendale GA, Santoro N, Habel LA, Reeves KW. Anti-Müllerian hormone levels and breast cancer risk in the study of women’s health across the nation. Cancer Causes Control. 2022 Aug;33(8):1039-1046. doi: 10.1007/s10552-022-01596-5. Epub 2022 Jun 29. PMID: 35768642.

The presented study addresses the current lack of literature addressing the relationship between AMH levels with breast cancer in women who do not identify as non-Hispanic and white, and gathered information from Chinese, Japanese, Black, Hispanic, and white women. This SWAN study measured AMH level by ELISA, and breast cancer history was assessed during a series of interviews. AMH measurements were available for 1,529 SWAN participants, 84 of which reported an incident of a breast cancer diagnosis. Subgroup analysis revealed the hazard ratio for continuous AMH was 1.11 (95% CI 0.92–1.34) for White women, 1.04 (95% CI 0.86–1.27) for Black women and 1.07 (95% CI 0.85–1.33) for Asian women. This study was not able to accurately assess the hazard ratio for Hispanic women due to low incidence of breast cancer in this subgroup. A non-significant, positive association was observed between AMH level and risk of breast cancer in pre- and perimenopausal women.

Previous
Previous

SPOTLIGHT ON THE GUT MICROBIOME IN MENOPAUSE: CURRENT INSIGHTS

Next
Next

CARDIOMETABOLIC MEASURES AND COGNITION IN EARLY MENOPAUSE - ANALYSIS OF BASELINE DATA FROM A RANDOMIZED CONTROLLED TRIAL.